ERBB2 and breast carcinoma: Notably, it has been reported that poor expression of microRNA-124 is a prognostic biomarker of breast cancer patients,while miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes (10-14) However, the role of miR-124 in HER2-positive breast cancer remains largely unknown.